About Heartscape Technologies, Inc.

Heartscape Technologies is engaged in the development and marketing of the PRIME ECG system, an FDA-approved medical device that accurately and rapidly diagnoses heart attacks and ischemia (restrictions in blood supply) in emergency cases. The PRIME ECG system consists of a rapidly-applied single use disposable plastic vest containing 80 data collection points which connect to a compact mobile computer workstation. A physician can view the heart’s electrical activity in either traditional ECG tracings or easily interpreted color-coded 3D graphics. The vest does not interfere with X-ray or other imaging tests and is already used in a number of US hospitals. Its chief advantage over standard ECG systems is that its enhanced diagnostic capabilities may enable earlier intervention, a central factor in reducing patient death and morbidity. Heartscape is also developing extensions to its existing PRIME technology, including a version of the vest that is planned to be used with pharmacologic and exercise-induced stress testing. 

Heartscape has sales and operation offices in the United States and R&D and manufacturing facilities in Northern Ireland. PRIME ECG (a registered trademark of Heartscape Technologies) was developed by Heartscape based on technology licensed from the University of Ulster and developed in collaboration with the Royal Victoria Hospital in Northern Ireland.

Clinical trials in nearly 3,000 patients over 12 years have consistently demonstrated the potential of PRIME ECG to deliver better results than a 12-lead standard ECG for the diagnosis of AMI (acute myocardial infarction). In late 2006, Heartscape initiated OCCULT-MI, a clinical trial designed to measure door to sheath time (DTST), in minutes, for PRIME-only STEMI (ST-elevation MI) patients vs. STEMI patients diagnosed by the standard 12-lead ECG. Time will be assessed from patient presentation to the hospital’s emergency department to the time of sheath insertion in the cardiac catheterization laboratory. Secondary endpoints will evaluate the impact of PRIME ECG on various measures including cost of care, clinical diagnosis and outcomes, and the role of PRIME ECG in assessing risk in patients with cardiac ischemia. The trial expects to enroll 1400 patients. Twelve centers are participating in the study, and more than 1200 patients have been enrolled to date.  Results are expected in the first half of 2008.

Funding for Heartscape Technologies has primarily been provided by the following venture capital firms: Scottish Equity Partners, Glasgow, Scotland; Investor Growth Capital, Stockholm, Sweden; Radius Ventures, New York; and, Delta Partners, Dublin, Ireland.

Read more about Heartscape Technologies at www.primeecg.com.